{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:32:13Z","timestamp":1791570733419,"version":"4.3.4"},"reference-count":108,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Can-Fite BioPharma Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The A3 adenosine receptor (A3AR) is a stress-inducible G-protein-coupled receptor that is selectively upregulated in inflamed, hypoxic, and fibrotic tissues as well as in many malignancies, while remaining weakly expressed in most normal organs. This distinctive expression pattern provides a strong biological basis for pathology-selective pharmacology. Activation of A3AR by highly selective agonists, including piclidenoson (IB-MECA) and namodenoson (Cl-IB-MECA), initiates signaling through Gi proteins and phospholipase C (PLC), which in turn regulate a coordinated network of downstream intracellular pathways, including PI3K\/Akt, NF-\u03baB, MAPKs, and Wnt\/\u03b2-catenin, resulting in suppression of inflammation, inhibition of pathological cell survival, and protection of metabolically stressed tissues. Over the three decades, extensive preclinical studies have demonstrated that A3AR agonism exerts anti-cancer, anti-fibrotic, immunomodulatory, neuroprotective, and organ-protective effects across diverse disease models, including hepatocellular carcinoma, pancreatic cancer, psoriasis, osteoarthritis, metabolic dysfunction-associated steatohepatitis, ischemic stroke, neurodegeneration, ophthalmic disorders, and inherited metabolic syndromes. Importantly, these mechanistic insights have been translated into clinical programs, with piclidenoson and namodenoson demonstrating favorable safety profiles and disease-modifying activity in inflammatory, fibrotic, and oncologic indications. This review integrates molecular, cellular, and translational evidence to highlight A3AR activation as a unifying therapeutic principle for diseases driven by inflammation, oxidative stress, hypoxia, and dysregulated cell survival, positioning selective A3AR agonists as first-in-class agents targeting the A3AR, with broad clinical applicability across multiple disease domains.<\/jats:p>","DOI":"10.3390\/biom16060907","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:43:57Z","timestamp":1782463437000},"page":"907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation"],"prefix":"10.3390","volume":"16","author":[{"given":"Pnina","family":"Fishman","sequence":"first","affiliation":[{"name":"Can-Fite BioPharma Ltd., Ramat Gan 5257346, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2003.11.003","article-title":"Adenosine: An endogenous regulator of innate immunity","volume":"25","author":"Cronstein","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/414916a","article-title":"Role of G-protein\u2013coupled adenosine receptors in downregulation of inflammation and protection from tissue damage","volume":"414","author":"Ohta","year":"2001","journal-title":"Nature"},{"key":"ref_4","first-page":"198","article-title":"Purinergic signalling: Pathophysiological roles","volume":"5","author":"Abbracchio","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cellimm.2009.03.020","article-title":"The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn\u2019s disease","volume":"258","author":"Ochaion","year":"2009","journal-title":"Cell. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1073\/pnas.90.21.10365","article-title":"Molecular cloning and characterization of the human A3 adenosine receptor","volume":"90","author":"Salvatore","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.89.16.7432","article-title":"Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor","volume":"89","author":"Zhou","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0028-3908(97)00104-4","article-title":"Pharmacological characterization of novel A3 adenosine receptor-selective antagonists","volume":"36","author":"Jacobson","year":"1997","journal-title":"Neuropharmacology"},{"key":"ref_9","first-page":"3561","article-title":"A3 adenosine receptor ligands: Structure\u2013activity relationships","volume":"11","author":"Gao","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1124\/mol.62.5.1167","article-title":"Regulation of the A3 adenosine receptor gene in vascular smooth muscle cells: Role of a cAMP and GATA element","volume":"62","author":"Yaar","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1593\/neo.05334","article-title":"adenosine receptors modulate hypoxia-inducible factor-1\u03b1 expression in human A375 melanoma cells","volume":"7","author":"Merighi","year":"2005","journal-title":"Neoplasia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","first-page":"1030","article-title":"Medicinal Chemistry of the A3 Adenosine Receptor: Agonists, Antagonists, and Receptor Engineering","volume":"9","author":"Jacobson","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert Its Protective Effects?","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bcp.2017.12.026","article-title":"A binding kinetics study of human adenosine A3 receptor agonists","volume":"153","author":"Xia","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11302-020-09715-0","article-title":"Design and In Vivo Activity of A3 Adenosine Receptor Agonist Prodrugs","volume":"16","author":"Suresh","year":"2020","journal-title":"Purinergic Signal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0026-895X(25)10571-3","article-title":"G protein\u2013dependent activation of phospholipase C by adenosine A3 receptors in rat brain","volume":"48","author":"Abbracchio","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/pr.113.008540","article-title":"The A3 adenosine receptor: History and perspectives","volume":"67","author":"Borea","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: From medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.21037\/atm-20-6154","article-title":"Adenosine A3 receptor activated in H2O2 oxidative stress of primary open-angle glaucoma","volume":"9","author":"Zhou","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-385526-8.00002-3","article-title":"Adenosine receptors in health and disease","volume":"61","author":"Gessi","year":"2011","journal-title":"Adv. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ajpath.2011.07.006","article-title":"A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats","volume":"179","author":"Choi","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pietrowski, M.J., Gabriele, M., Paolicelli, R.C., Maccarrone, M., Molinari, C., and Limatola, C. (2021). Glial purinergic signaling in neurodegeneration. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.654850"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.18632\/aging.202178","article-title":"Activation of adenosine A3 receptor reduces early brain injury by alleviating neuroinflammation after subarachnoid hemorrhage in elderly rats","volume":"13","author":"Li","year":"2020","journal-title":"Aging"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Borea, P.A. (2010). Agonists and antagonists: Molecular mechanisms and therapeutic applications. A3 Adenosine Receptors: From Cell Biology to Pharmacology and Therapeutics, Springer.","DOI":"10.1007\/978-90-481-3144-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/(SICI)1098-1128(200003)20:2<103::AID-MED1>3.0.CO;2-X","article-title":"A3 adenosine receptor ligands: History and perspectives","volume":"20","author":"Baraldi","year":"2000","journal-title":"Med. Res. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1073\/pnas.95.12.6995","article-title":"A physiological role of the adenosine A3 receptor: Sustained cardio protection","volume":"95","author":"Liang","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41419-020-2593-y","article-title":"Activation of adenosine A3 receptor protects retinal ganglion cells from degeneration induced by ocular hypertension","volume":"11","author":"Boia","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00422.2014","article-title":"Identification and function of adenosine A3 receptor in afferent arterioles","volume":"308","author":"Lu","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/187152207781369878","article-title":"The anti-cancer effect of A3 adenosine receptor agonists: A novel targeted therapy","volume":"7","author":"Fishman","year":"2007","journal-title":"Immunol. Endocr. Metab. Agents Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/13543784.2011.573785","article-title":"Investigational A3 adenosine receptor targeting agents","volume":"20","author":"Pacher","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_32","first-page":"2896","article-title":"A3 adenosine receptor activation mechanisms: Molecular dynamics analysis of inactive, active, and fully active states","volume":"60","author":"Ciancetta","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002320010018","article-title":"Activation of A3 adenosine receptor induces calcium entry and chloride secretion in A6 cells","volume":"178","author":"Reshkin","year":"2000","journal-title":"J. Membr. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1573403X12666160111125116","article-title":"Adenosine A3 receptor: A promising therapeutic target in cardiovascular disease","volume":"12","author":"Nishat","year":"2016","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrm908","article-title":"Seven-transmembrane receptors","volume":"3","author":"Pierce","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000339058","article-title":"A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells","volume":"30","author":"Otsuki","year":"2012","journal-title":"Cell Physiol. Biochem."},{"key":"ref_37","first-page":"2077","article-title":"Targeting the A3 adenosine receptor for cancer therapy: Inhibition of prostate carcinoma cell growth by an A3AR agonist","volume":"23","author":"Fishman","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1038\/sj.onc.1205531","article-title":"Evidence for involvement of Wnt signaling pathway in IB-MECA\u2013mediated suppression of melanoma cells","volume":"21","author":"Fishman","year":"2002","journal-title":"Oncogene"},{"key":"ref_39","first-page":"287","article-title":"The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-\u03baB signal transduction pathways","volume":"33","author":"Stemmer","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Itzhak, I., Bareket-Samish, A., and Fishman, P. (2023). Namodenoson inhibits the growth of pancreatic carcinoma via deregulation of the Wnt\/\u03b2-catenin, NF-\u03baB, and Ras signaling pathways. Biomolecules, 13.","DOI":"10.3390\/biom13111584"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2003.08.031","article-title":"Adenosine A3 receptor-mediated regulation of p38 and ERK1\/2 via phosphatidylinositol-3\u2032-kinase","volume":"67","author":"Hammarberg","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41388-021-02090-z","article-title":"Cancer biology and molecular genetics of A3 adenosine receptor","volume":"41","author":"Mazziotta","year":"2022","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0167-4889(02)00248-3","article-title":"Involvement of the mitogen\u2013activated protein kinase cascade in agonist-mediated phosphorylation and regulation of A3 adenosine receptors","volume":"1591","author":"Trincavelli","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11302-007-9086-7","article-title":"Internalization and desensitization of adenosine receptors","volume":"4","author":"Klaasse","year":"2008","journal-title":"Purinergic Signal."},{"key":"ref_45","first-page":"e93950","article-title":"Adenosine A3 receptor and its potential role in cancer treatment: A narrative review","volume":"17","author":"Pergolizzi","year":"2025","journal-title":"Cureus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40478-022-01315-w","article-title":"Targeting the A3 adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice","volume":"10","author":"Singh","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_47","first-page":"1","article-title":"The role of extra-cellular adenosine receptors in modulating pain progression during osteoarthritis (OA): A systematic review of the literature","volume":"3","author":"Weaver","year":"2018","journal-title":"Rheumatol. Orthop. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1111\/jcmm.17438","article-title":"Activation of adenosine A3 receptor attenuates progression of osteoarthritis through inhibiting the NLRP3\/caspase-1\/GSDMD induced signalling","volume":"26","author":"Bai","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1268242024","DOI":"10.1523\/JNEUROSCI.1268-24.2024","article-title":"Mitochondrial A3 adenosine receptor as a mechanism for the protective effects of A3AR agonists on chemotherapy-induced neuropathic pain","volume":"45","author":"Doyle","year":"2025","journal-title":"J. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.3390\/ijms25115763","article-title":"Adenosine A3 receptor: From molecular signaling to therapeutic target in pathological heart conditions","volume":"25","author":"Duangrat","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11302-023-09925-2","article-title":"Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: Anti-cancer and hepatoprotective effects","volume":"19","author":"Fishman","year":"2023","journal-title":"Purinergic Signal."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jcp.20994","article-title":"Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: Focus on the A3 adenosine subtype","volume":"211","author":"Gessi","year":"2007","journal-title":"J. Cell Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00109-018-1680-3","article-title":"Genetic ablation of adenosine receptor A3 results in articular cartilage degeneration","volume":"96","author":"Shkhyan","year":"2018","journal-title":"J. Mol. Med."},{"key":"ref_54","unstructured":"Corciulo, C., Lendhey, M., Wilder, T., Schoen, H., Cornelissen, A.S., Chang, G., Kennedy, O.D., and Cronstein, B.N. (2023). Purines and Adenosine Receptors in Osteoarthritis. Biomolecules, 13."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.7150\/ijbs.113585","article-title":"The function of GPCRs in different bone cells","volume":"21","author":"Zhang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/art.24817","article-title":"Induction of an anti-inflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment","volume":"60","author":"Ochaion","year":"2009","journal-title":"Arthritis Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hanf, R., Bareket-Samish, A., Moulin, P., Manias, F., Seguela, J., Baulez, B., Sutre, V., Koch, J.B., Salindre, J., and Dubruque, M. (2026). Piclidenoson, an A3 Adenosine Receptor Agonist, Demonstrates Clinical Benefit in Canine Osteoarthritis: A Pilot Study. Front. Vet. Sci., 13.","DOI":"10.3389\/fvets.2026.1847566"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"108274","DOI":"10.1016\/j.phrs.2026.108274","article-title":"Adenosine Receptors in Blood Cells: Biomarkers and Beyond","volume":"230","author":"Merighi","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1517\/13543784.16.10.1601","article-title":"The anti-inflammatory effect of A3 adenosine receptor agonists: A novel targeted therapy for rheumatoid arthritis","volume":"16","author":"Silverman","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105731","DOI":"10.1016\/j.phrs.2021.105731","article-title":"Optical control of adenosine A3 receptor function in psoriasis","volume":"170","author":"Filgaira","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_61","first-page":"2256","article-title":"The he A3 adenosine receptor (A3AR) agonist namodenoson ameliorates non-alcoholic steatohepatitis in mice","volume":"44","author":"Fishman","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(98)00977-7","article-title":"Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: Neuronal and glial effects","volume":"367","author":"Lin","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1016\/j.cell.2025.06.002","article-title":"Deconstructing the intercellular interactome in vascular dementia with focal ischemia for therapeutic applications","volume":"188","author":"Tian","year":"2025","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.pain.2014.09.016","article-title":"A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways","volume":"155","author":"Janes","year":"2014","journal-title":"Pain"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/ijmm.2022.5086","article-title":"2-Cl-IB-MECA regulates the proliferative and drug resistance pathways and facilitates chemosensitivity in pancreatic and liver cancer cell lines","volume":"49","author":"Kotulova","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0959-8049(00)00130-1","article-title":"Adenosine acts as an inhibitor of lymphoma cell growth: A major role for the A3 adenosine receptor","volume":"36","author":"Fishman","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00001813-200206000-00001","article-title":"A3 adenosine receptor as a target for cancer therapy","volume":"13","author":"Fishman","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/jcb.25945","article-title":"A3 adenosine receptor agonist inhibited survival of breast cancer stem cells via GLI-1 and ERK1\/2 pathway","volume":"118","author":"Jafari","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"Mortezaee","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2012-0211","article-title":"CF102 for the treatment of hepatocellular carcinoma: A phase I\/II, open-label, dose-escalation study","volume":"18","author":"Stemmer","year":"2013","journal-title":"Oncologist"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Stemmer, S.M., Manojlovic, N.S., Marinca, M.V., Petrov, P., Cherciu, N., Ganea, D., Ciuleanu, T.E., Pusca, I.A., Beg, M.S., and Purcell, W.T. (2021). Namodenoson in advanced hepatocellular carcinoma and Child\u2013Pugh B cirrhosis: Randomized placebo-controlled clinical trial. Cancers, 13.","DOI":"10.3390\/cancers13020187"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Fishman, P. (2022). Drugs targeting the A3 adenosine receptor: Human clinical study data. Molecules, 27.","DOI":"10.3390\/molecules27123680"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: A phase II double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12974-020-02009-7","article-title":"Adenosine A3 receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury","volume":"17","author":"Farr","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"El-Naggar, A.E., Helmy, M.M., El-Gowilly, S.M., and El-Mas, M.M. (2024). Suppression by central adenosine A3 receptors of the cholinergic defense against cardiovascular aberrations of sepsis: Role of PI3K\/MAPKs\/NF-\u03baB signaling. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1418981"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ferreira-Silva, J., Aires, I.D., Boia, R., Ambr\u00f3sio, A.F., and Santiago, A.R. (2020). Activation of adenosine A3 receptor inhibits microglia reactivity elicited by elevated pressure. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197218"},{"key":"ref_79","first-page":"237","article-title":"Gene regulation in activated microglia by adenosine A3 receptor agonists: A transcriptomics study","volume":"20","author":"Lillo","year":"2024","journal-title":"Neurochem. Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2310970","DOI":"10.1155\/2018\/2310970","article-title":"Inhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist piclidenoson","volume":"2018","author":"Cohen","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/DDDT.S195294","article-title":"Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy","volume":"13","author":"Cohen","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2298\/VSP241004010K","article-title":"Anti-inflammatory properties of an A3 adenosine receptor agonist, piclidenoson, in a model of human peripheral blood mononuclear cell culture","volume":"82","author":"Drakul","year":"2025","journal-title":"Vojnosanit. Pregl."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"R197","DOI":"10.1186\/ar3527","article-title":"A2A and A3 adenosine receptor expression in rheumatoid arthritis: Upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release","volume":"13","author":"Varani","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"818251","DOI":"10.1155\/2014\/818251","article-title":"Activation of adenosine A3 receptor alleviates TNF-\u03b1-induced inflammation through inhibition of the NF-\u03baB signaling pathway in human colonic epithelial cells","volume":"2014","author":"Ren","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_85","first-page":"41","article-title":"Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: Data from a phase II clinical trial","volume":"35","author":"Silverman","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_86","first-page":"2","article-title":"Therapeutic Effect of Oral CF101 in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Phase II Study","volume":"11","author":"Bagaria","year":"2015","journal-title":"Immunome Res."},{"key":"ref_87","first-page":"1708","article-title":"The efficacy and safety of piclidenoson vs. methotrexate in early rheumatoid arthritis: Phase III randomized, double-blind, placebo-controlled study","volume":"73","author":"Reitblat","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","article-title":"Treatment of plaque-type psoriasis with oral CF101: Data from an exploratory randomized phase II clinical trial","volume":"26","author":"David","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","first-page":"931","article-title":"Treatment of plaque-type psoriasis with oral CF101: Data from a phase II\/III multicenter, randomized, controlled trial","volume":"15","author":"David","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jdv.19811","article-title":"Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase III clinical trial (COMFORT-1)","volume":"38","author":"Papp","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Salmaso, V., Menin, S., Moro, S., Spalluto, G., and Federico, S. (2025). Adenosine receptors in neuroinflammation and neurodegeneration. Cells, 14.","DOI":"10.3390\/cells14201585"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1097\/j.pain.0000000000003242","article-title":"Analgesic candidate adenosine A3 receptors are expressed by perineuronal peripheral macrophages in human dorsal root ganglion and spinal cord microglia","volume":"165","author":"Sapio","year":"2024","journal-title":"Pain"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/brain\/awu330","article-title":"Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states","volume":"138","author":"Little","year":"2015","journal-title":"Brain"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.ynpai.2022.100087","article-title":"Adenosine receptors: Emerging non-opioid targets for pain medications","volume":"11","author":"Jung","year":"2022","journal-title":"Neurobiol. Pain"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"174874","DOI":"10.1016\/j.ejphar.2022.174874","article-title":"A3 Adenosine Receptor Agonist IB-MECA Reverses Chronic Cerebral Ischemia-Induced Inhibitory Avoidance Memory Deficit","volume":"921","author":"Cheng","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Vincenzi, F., Pasquini, S., Contri, C., Cappello, M., Nigro, M., Travagli, A., Merighi, S., Gessi, S., Borea, P.A., and Varani, K. (2023). Pharmacology of adenosine receptors: Recent advancements. Biomolecules, 13.","DOI":"10.3389\/fphar.2022.1030895"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JAD-142223","article-title":"Caffeine, through adenosine A3 receptor-mediated actions, suppresses amyloid-\u03b2 protein precursor internalization and amyloid-\u03b2 generation","volume":"47","author":"Li","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1111\/jcmm.17315","article-title":"Single-nucleus transcriptome analysis reveals disease- and regeneration-associated endothelial cells in white matter vascular dementia","volume":"26","author":"Mitroi","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.108.810101","article-title":"Adenosine A3 receptor and cardioprotection: Enticing, enigmatic, elusive","volume":"118","author":"Rothermel","year":"2008","journal-title":"Circulation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"H228","DOI":"10.1152\/ajpheart.1999.277.1.H228","article-title":"Adenosine A3-receptor stimulation attenuates postischemic dysfunction through KATP channels","volume":"277","author":"Thourani","year":"1999","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"H607","DOI":"10.1152\/ajpheart.01001.2002","article-title":"A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia\u2013reperfusion injury in dogs","volume":"285","author":"Auchampach","year":"2003","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1074248410396877","article-title":"Adenosine receptor-mediated cardioprotection: Are all 4 subtypes required or redundant?","volume":"17","author":"McIntosh","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1007209321969","article-title":"Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes","volume":"217","author":"Safran","year":"2001","journal-title":"Mol. Cell. Biochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1006\/jmcc.2001.1387","article-title":"Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity","volume":"33","author":"Shneyvays","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_105","first-page":"937","article-title":"Identification of the A3 adenosine receptor in rat retinal ganglion cells","volume":"12","author":"Zhang","year":"2006","journal-title":"Mol. Vis."},{"key":"ref_106","first-page":"727","article-title":"Inhibition of experimental autoimmune uveitis by the A3 adenosine receptor agonist CF101","volume":"28","author":"Luger","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"ref_107","first-page":"491","article-title":"Targeting the A3 adenosine receptor for glaucoma treatment (Review)","volume":"30","author":"Fishman","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1720452","DOI":"10.3389\/fcell.2025.1720452","article-title":"Clinical variation in Lowe syndrome: What and how?","volume":"13","author":"Brewer","year":"2025","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:07:41Z","timestamp":1782468461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":108,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["biom16060907"],"URL":"https:\/\/doi.org\/10.3390\/biom16060907","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}